No FDA Compromise On Veregen Specifications In First Botanical NDA Review
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The first botanical NDA, MediGene’s Veregen (kunecatechins), illuminated gaps in the emerging regulatory framework for plant-derived prescription drugs, FDA review documents indicate.
You may also be interested in...
US FDA’s Botanical Drugs Guidance Will See Rare Outing For Amryt’s Filsuvez NDA
Amryt’s birch bark extract oleogel-S10 for Epidermolysis Bullosa patients might become only the third botanical drug to clear the FDA.
A Question Of Identity: Drug & Botanical Perspectives On Manufacturing Clash In Fulyzaq Review
Salix’ botanical product Fulyzaq tested the limits of the conventional small molecule chemistry approach to ensuring the identity of drug substance. After a regulatory briefing with CDER Director Woodcock, the botanicals and CMC review teams agreed on a bioassay to bridge the gap in their regulatory perspectives.
NME Slump Continues: FDA Clears 18 Novel Drugs In 2006, Same As 2005
FDA's final approval tally of new molecular entities in 2006 is almost a 25-year low, despite early signs that the agency was on pace to best last year's final count of NME approvals